Lifecore Biomedical (LFCR) risk factors

The company relies heavily on customer concentration, notably Alcon, which accounts for 44 percent of revenue and provides a $173.5 million loan. Financial controls are constrained by material weaknesses and a history of net losses, including a $38.7 million loss in fiscal 2025. Operations depend entirely on three Chaska, Minnesota manufacturing facilities and single-source suppliers for hyaluronic acid products.